HAG
NYMX

HighPoint Advisor Group’s Nymox Pharmaceutical Corp NYMX Stock Holding History

HighPoint Advisor Group’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-34,000
Closed -$73K – 509
2020
Q3 		$73K Hold
34,000
– – 0.01% 379
2020
Q2 		$123K Hold
34,000
– – 0.03% 331
2020
Q1 		$98K Hold
34,000
– – 0.02% 320
2019
Q4 		$102K Buy
+34,000
New +$67.1K 0.02% 351

Other funds holding NYMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HighPoint Advisor Group's NYMX Position: Q4 2020 in Review

HighPoint Advisor Group sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2020, closing a stake of 34,000 shares — an estimated $73K sold.

HighPoint Advisor Group first reported a position in NYMX in Q4 2019 and held it in 4 quarters. The position peaked at $123K in Q2 2020. 58 funds tracked by Wall St. Rank hold NYMX as of Q4 2020.

  • HighPoint Advisor Group reported no remaining Nymox Pharmaceutical Corp position as of Q4 2020 after selling out during the quarter.
  • HighPoint Advisor Group sold 34,000 Nymox Pharmaceutical Corp shares in Q4 2020, an estimated $73K.
  • HighPoint Advisor Group first reported a position in Nymox Pharmaceutical Corp in Q4 2019 and held it in 4 quarters.
  • HighPoint Advisor Group's Nymox Pharmaceutical Corp position peaked at $123K in Q2 2020.
  • 58 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2020.

Based on HighPoint Advisor Group's 13F filing for Q4 2020, filed 10 Feb 2021.